Is it Real? Qualitative Framing Analyses of the Depiction of Fibromyalgia in Newspapers and Health Websites

Abstract Purpose: This two-phase project employed qualitative framing analyses to explore how fibromyalgia has been framed in some of the top sources of U.S. health information and how these sources address treatments related to fibromyalgia. Methods: Phase 1 of the project examined 95 stories and article

The effects of thymoquinone on pancreatic cancer: Evidence from preclinical studies

Thymoquinone (TQ) is a secondary metabolite found in abundance in very few plant species including Nigella sativa L., Monarda fistulosa L., Thymus vulgaris L. and Satureja montana L. Preclinical pharmacological studies have shown that TQ has many biological activities, such as anti-inflammatory, antioxidant and anticancer. Both in vivo and in vitro experiments have shown that TQ acts as an antitumor agent by altering cell cycle progression, inhibiting cell proliferation, stimulating apoptosis, inhibiting angiogenesis, reducing metastasis and affecting autophagy. In this comprehensive study, the evidence on the pharmacological potential of TQ on pancreatic cancer is reviewed. The positive results of preclinical studies support the view that TQ can be considered as an additional therapeutic agent against pancreatic cancer. The possibilities of success for this compound in human medicine should be further explored through clinical trials. © 2022 The Author

Stomatal Density and its Relationship with Yield of Radish (Raphanus Sativus L.) Fertilized with Biol Produced from Sugar Cane Residues

The impact of agro-industrial waste can be reduced by using it in crop fertilization. The aim of this study was to evaluate the stomatal density and yield of radish (Raphanus Sativus L.) fertilized with biol at different concentrations, produced from sugar cane residues. A completely randomized blocks design statistical model was used, which consisted of 5 tests with 3 repetitions for each one, being T1 the control trial, and T2, T3, T4 and T5 the treatments using 2, 3, 4 and 5 L of biol in 200 L of water respectively. In terms of crop physical characteristics, the T5 treatment excelled in plant length, equatorial diameter, plant weight, as well as yield with 12.71 t/ha. Likewise, in the chemical analysis of the radish leaves, the T5 treatment showed an increase in K, Ca, Zn and MN, while the T2 did it in N, P and Cu, the T3 in Fe and the T4 in Mg. In terms of stomatal density, T5 stood out with 122 stomatal/mm2. Based on this, it is concluded that the increase in the dose of biol influences the increase in nutrient and stomatal density and hence the yield of the radish crop

Microbiota alterations in proline metabolism impact depression

The microbiota-gut-brain axis has emerged as a novel target in depression, a disorder with low treatment efficacy. However, the field is dominated by underpowered studies focusing on major depression not addressing microbiome functionality, compositional nature, or confounding factors. We applied a multi-omics approach combining pre-clinical models with three human cohorts including patients with mild depression. Microbial functions and metabolites converging onto glutamate/GABA metabolism, particularly proline, were linked to depression. High proline consumption was the dietary factor with the strongest impact on depression. Whole-brain dynamics revealed rich club network disruptions associated with depression and circulating proline. Proline supplementation in mice exacerbated depression along with microbial translocation. Human microbiota transplantation induced an emotionally impaired phenotype in mice and alterations in GABA-, proline-, and extracellular matrix-related prefrontal cortex genes. RNAi-mediated knockdown of proline and GABA transporters in Drosophila and mono-association with L. plantarum, a high GABA producer, conferred protection against depression-like states. Targeting the microbiome and dietary proline may open new windows for efficient depression treatment

Risks of dengue secondary infective biting associated with aedes aegypti in home environments in Monterrey, Mexico

Abstract. Secondary dengue virus infections are a major risk for developing dengue hemorrhagic fever. Recent exposure to infectious bites of Aedes aegypti (L.) females in previously diagnosed dengue cases fulfills the epidemiological model of dengue hemorrhagic fever. A study was comprised of 357 (89.2%) dengue and 43 (10.8%) dengue hemorrhagic fever cases confirmed by laboratory tests and clinical manifestations. An entomological survey was done in homes and backyards. Concurrently, a questionnaire was used to assess the impact of healthpromotion campaigns through knowledge of the vector and its epidemiological role. Seventy-six (28.4%) of the 268 (67.0%) total wet or dry oviposition sites were positive for the presence of larvae or pupae, while adult Ae. aegypti were found in 32 (8.0%). One hundred thirty-two (33%) householders who formerly had dengue fever or dengue hemorrhagic fever had knowledge of either larval or adult dengue vector stages. According to gender distribution, 145 (36.2%) and 14 (3.5%) of the males confirmed with cases of dengue and dengue hemorrhagic fever lived in houses with 17.9 and 2% of the Ae. aegypti larval and pupal habitats. Houses with females who had dengue and dengue hemorrhagic fever were 212 (53%) and 29 (7.3%), with containers with immature Ae. aegypti in 19.4 and 7%, respectively. Lack of sustainability of government-targeted health education campaigns is the major problem for involving communities in prevention and control of dengu

Bladder cancer index: cross-cultural adaptation into Spanish and psychometric evaluation

BACKGROUND: The Bladder Cancer Index (BCI) is so far the only instrument applicable across all bladder cancer patients, independent of tumor infiltration or treatment applied. We developed a Spanish version of the BCI, and assessed its acceptability and metric properties. METHODS: For the adaptation into Spanish we used the forward and back-translation method, expert panels, and cognitive debriefing patient interviews. For the assessment of metric properties we used data from 197 bladder cancer patients from a multi-center prospective study. The Spanish BCI and the SF-36 Health Survey were self-administered before and 12 months after treatment. Reliability was estimated by Cronbach's alpha. Construct validity was assessed through the multi-trait multi-method matrix. The magnitude of change was quantified by effect sizes to assess responsiveness. RESULTS: Reliability coefficients ranged 0.75-0.97. The validity analysis confirmed moderate associations between the BCI function and bother subscales for urinary (r = 0.61) and bowel (r = 0.53) domains; conceptual independence among all BCI domains (r ≤ 0.3); and low correlation coefficients with the SF-36 scores, ranging 0.14-0.48. Among patients reporting global improvement at follow-up, pre-post treatment changes were statistically significant for the urinary domain and urinary bother subscale, with effect sizes of 0.38 and 0.53. CONCLUSIONS: The Spanish BCI is well accepted, reliable, valid, responsive, and similar in performance compared to the original instrument. These findings support its use, both in Spanish and international studies, as a valuable and comprehensive tool for assessing quality of life across a wide range of bladder cancer patients

Correction to: Aphid and caterpillar feeding drive similar patterns of induced defences and resistance to subsequent herbivory in wild cotton

Correction to: Planta (2023) 258:113 https://doi.org/10.1007/s00425-023-04266-1Peer reviewe

Clinical intervals and diagnostic characteristics in a cohort of prostate cancer patients in Spain: a multicentre observational study

Background: Little is known about the healthcare process for patients with prostate cancer, mainly because hospital-based data are not routinely published. The main objective of this study was to determine the clinical characteristics of prostate cancer patients, the diagnostic process and the factors that might influence intervals from consultation to diagnosis and from diagnosis to treatment. Methods: We conducted a multicentre, cohort study in seven hospitals in Spain. Patients' characteristics and diagnostic and therapeutic variables were obtained from hospital records and patients' structured interviews from October 2010 to September 2011. We used a multilevel logistic regression model to examine the association between patient care intervals and various variables influencing these intervals (age, BMI, educational level, ECOG, first specialist consultation, tumour stage, PSA, Gleason score, and presence of symptoms) and calculated the odds ratio (OR) and the interquartile range (IQR). To estimate the random inter-hospital variability, we used the median odds ratio (MOR). Results: 470 patients with prostate cancer were included. Mean age was 67.8 (SD: 7.6) years and 75.4 % were physically active. Tumour size was classified as T1 in 41.0 % and as T2 in 40 % of patients, their median Gleason score was 6.0 (IQR:1.0), and 36.1 % had low risk cancer according to the D'Amico classification. The median interval between first consultation and diagnosis was 89 days (IQR:123.5) with no statistically significant variability between centres. Presence of symptoms was associated with a significantly longer interval between first consultation and diagnosis than no symptoms (OR:1.93, 95%CI 1.29-2.89). The median time between diagnosis and first treatment (therapeutic interval) was 75.0 days (IQR:78.0) and significant variability between centres was found (MOR:2.16, 95%CI 1.45-4.87). This interval was shorter in patients with a high PSA value (p = 0.012) and a high Gleason score (p = 0.026). Conclusions: Most incident prostate cancer patients in Spain are diagnosed at an early stage of an adenocarcinoma. The period to complete the diagnostic process is approximately three months whereas the therapeutic intervals vary among centres and are shorter for patients with a worse prognosis. The presence of prostatic symptoms, PSA level, and Gleason score influence all the clinical intervals differently

Consensus statement for the management of Acute Coronary Syndromes and the COVID-19 pandemic

Los servicios de cardiología de Argentina deben estar preparados para manejar pacientes con patología cardíaca aguda en el contexto de la pandemia del coronavirus (COVID-19)1. Los pacientes con infección COVID-19 que tengan manifestaciones más graves serán derivados a la unidad de cuidados intensivos y aquellos con síntomas leves a moderados serán manejados en sala de medicina general. Cuando ambas áreas estén completamente llenas, comenzaremos a recibir pacientes en la unidad de cardiología. El síndrome coronario agudo (SCA) no escapa a esta realidad. El personal médico, enfermeros, técnicos deben conocer la problemática, recibir capacitación acerca de cómo protegerse y prevenir la infección en sus pacientes, cuándo y cómo aislar a los mismos una vez infectados, así como conocer el equipo de protección que se debe utilizar. Por otro lado toda situación de estrés social como el que está creando esta pandemia en la población argentina, produce un incremento de eventos y muerte cardiovascular2 La asociación entre la enfermedad respiratoria viral y el riesgo de enfermedad cardiovascular posterior ha sido bien establecida; infecciones agudas, particularmente influenza, se han relacionado a infarto de miocardio y descompensación de insuficiencia cardíaca. Pacientes con infarto agudo de miocardio (IAM) acompañado de fiebre, especialmente con síntomas respiratorios, primero deberían ser derivados a un SECTOR para EVALUACIÓN DEL CUADRO. El sector que determine cada institución, dispondrá de un lugar en UCO-UTI y/o cardiología.publishedVersionFil: Muntaner, Juan A. Universidad Nacional de Tucumán. Facultad de Medicina. Centro Modelo de Cardiología; Argentina.Fil: Muntaner, Juan A. Federación Argentina de Cardiología. Comité de Cardiopatía Isquémica; Argentina.Fil: Ramos, Hugo R. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas; Argentina.Fil: Ramos, Hugo R. Instituto Modelo de Cardiología; Argentina.Fil: Ramos, Hugo R. Federación Argentina de Cardiología. Comité de Cardiopatía Isquémica; Argentina.Fil: Macín, Stella M. Universidad Nacional del Nordeste. Facultad de Medicina; Argentina.Fil: Macín, Stella M. Instituto de Cardiología de Corrientes; Argentina.Fil: Macín, Stella M. Federación Argentina de Cardiología. Comité de Cardiopatía Isquémica; Argentina.Fil: Bono, Julio O. Universidad Católica de Córdoba. Facultad de Medicina; Argentina.Fil: Bono, Julio O. Sanatorio Allende Nueva Córdoba, Argentina.Fil: Bono, Julio O. Federación Argentina de Cardiología. Comité de Cardiopatía Isquémica; Argentina.Fil: Zapata, Gerardo O. Universidad Nacional de Rosario. Facultad de Medicina; Argentina.Fil: Zapata, Gerardo O. Universidad Nacional de Rosario. Facultad de Medicina; Argentina.Fil: Zapata, Gerardo O. Instituto Cardiovascular de Rosario; Argentina.Fil: Zapata, Gerardo O. Federación Argentina de Cardiología. Comité de Cardiopatía Isquémica; Argentina.Fil: Zoni, Rodrigo. Instituto de Cardiología de Corrientes; Argentina.Fil: Zoni, Rodrigo. Federación Argentina de Cardiología. Comité de Cardiopatía Isquémica; Argentina.Fil: Atencio, Lorena. Instituto del Corazón San Rafael, Mendoza; Argentina.Fil: Atencio, Lorena. Federación Argentina de Cardiología. Comité de Cardiopatía Isquémica; Argentina.Fil: Fernández Cid, Gerardo. Ex Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires; Argentina.Fil: Fernández Cid, Gerardo. Federación Argentina de Cardiología. Comité de Cardiopatía Isquémica; Argentina.Fil: Barcudi, Raúl J. Universidad Católica de Córdoba. Facultad de Medicina; Argentina.Fil: Barcudi, Raúl J. Clínica Universitaria Reina Fabiola, Córdoba; Argentina.Fil: Barcudi, Raúl J. Federación Argentina de Cardiología. Comité de Cardiopatía Isquémica; Argentina.Fil: Paterlini, Gustavo A. Universidad Nacional de Tucumán. Facultad de Medicina; Argentina.Fil: Paterlini, Gustavo A. Hospital Zenón Santillán, Tucumán; Argentina.Fil: Paterlini, Gustavo A. Federación Argentina de Cardiología. Comité de Cardiopatía Isquémica; Argentina.Fil: Suasnabar, Ramón. Nueva Clínica Chacabuco, Tandil, Buenos Aires; Argentina.Fil: Suasnabar, Ramón. Federación Argentina de Cardiología. Comité de Cardiopatía Isquémica; Argentina.Fil: Mauro, Daniel O. Instituto del Corazón San Rafael, San Rafael, Mendoza; ArgentinaFil: Mauro, Daniel O. Federación Argentina de Cardiología. Comité de Cardiopatía Isquémica; Argentina.Fil: Moisés Azize, Guillermo. Hospital Córdoba; Argentina.Fil: Moisés Azize, Guillermo. Sanatorio Aconcagua, Córdoba; Argentina.Fil: Moisés Azize, Guillermo. Federación Argentina de Cardiología. Comité de Cardiopatía Isquémica; Argentina.Fil: Rengel, Esteban. Hospital General Lamadrid, Monteros, Tucumán; Argentina.Fil: Rengel, Esteban. Federación Argentina de Cardiología. Comité de Cardiopatía Isquémica; Argentina.Fil: Amoroso, Alejandro. Hospital San Bernardo, Salta; Argentina.Fil: Amoroso, Alejandro. Federación Argentina de Cardiología. Comité de Cardiopatía Isquémica; Argentina